莫索尼定治疗老年原发性高血压31例

目的评价莫索尼定在老年原发性高血压患者中的降压疗效、耐药性及安全性。方法选择31例≥70岁的老年性、轻中度原发性高血压患者，口服莫索尼定0.2～0.4 mg·d^-1，分别检测服药前和服药后第1，2，4和8周的收缩/舒张压、心率和血糖，并测定服药前和服药后第8周血液钾离子(K＋)、钠离子(Na＋)、尿素氮(BUN)、肌酐(Cr)、天冬氨酸氨基转移酶(AST)和丙氨酸氨基转移酶(ALT)水平，同时观察不良反应。结果治疗8周总有效率91.7%，收缩压和舒张压下降，用药后心率有所下降，其他生化指标无显著性改变。仅有1例出现Ⅰ度房室传导阻滞，用药减量后消失。长期服用疗效持续，并具有良好的耐受性。结论莫索尼定治疗≥70岁老年轻、中度原发性高血压安全有效。

Clinical Effect of Moxonidine on Aged Patients with Mild to Moderate Essential Hypertension

Objective To evaluate the efficacy, tolerance and safety of moxonidine on aged patients with mild to moderate essential hypertension. Methods Thirty-one patients over seventy with mild to moderate essential hypertension were given moxonidine orally, 0.2-0.4 mg, qd, for 8 weeks. Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate and blood glucose of the patients before the treatment and at 1, 2, 4 and 8 wk were tested, and the serum level of K~( ), Na~( ), BUN, Cr, AST and ALT before and after the treatment were measured. Results The SBP, DBP and heart rate declined remarkably after 1, 2, 4 and 8 wk. The level of K~( ), Na~( ), BUN, Cr, AST, ALT and serum glucose have no significant difference before and after the treatment. The total efficacy rate of moxonidine was 91.7%. Moxonidine had long therapeutic effect with good tolerance. Only one patient had adverse reaction. Conclusion Moxonidine has certain antihypertive effect and good safety on aged patients with mild to moderate essential hypertension.